新华制药：喷他佐辛注射液取得药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration of its injection product, Sufentanil Injection, which is indicated for various types of severe chronic pain [1] Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Sufentanil Injection [1] - Sufentanil is a partial agonist of opioid receptors, functioning by inhibiting the central nervous system's conduction system to provide analgesic effects [1] Group 2: Indications and Uses - The product is suitable for various chronic severe pain conditions, including cancer pain, traumatic pain, and postoperative pain [1] - It can also be used as an adjunct medication for anesthesia before surgery or during anesthesia induction [1]